NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

HIV(人類免疫缺陷病毒)藥物全球市場:按藥物類別的市場機會分析和行業預測(2020-2027)

Global HIV Drugs Market By Medication Class : Opportunity Analysis and Industry Forecast, 2020-2027

出版商 Allied Market Research 商品編碼 980719
出版日期 內容資訊 英文 237 Pages
商品交期: 2-3個工作天內
價格
HIV(人類免疫缺陷病毒)藥物全球市場:按藥物類別的市場機會分析和行業預測(2020-2027) Global HIV Drugs Market By Medication Class : Opportunity Analysis and Industry Forecast, 2020-2027
出版日期: 2020年11月20日內容資訊: 英文 237 Pages
簡介

2019年全球HIV藥物市場價值為30,891.48百萬美元,從2020年到2027年的複合年增長率為3.8%,到2027年有望將達到36,495.47百萬美元。

人類免疫缺陷病毒(HIV)攻擊人體的免疫系統,完全破壞免疫系統,並使宿主免疫系統易受感染。該病毒攻擊CD4細胞。 CD4細胞的主要作用是幫助免疫系統預防感染。這種攻擊破壞了人體的前線防禦,並使之暴露於各種傳染病中。艾滋病毒是世界上最令人困擾和廣泛傳播的疾病之一。 HIV感染的主要傳播途徑是無保護的性交,使用受污染的針頭,從感染HIV的母親到其後代的母乳餵養以及受感染的血液。

全球HIV毒品市場按毒品類別和地區分類。按藥物類別,市場是多類複合藥物,核甘逆轉錄□抑制劑(NRTI),非核甘逆轉錄□抑制劑(NNRTI),蛋白□抑制劑(PI),侵襲抑制劑和HIV整合□鏈轉移。它被歸類為抑制劑。在藥物類別中,由於使用了用於治療HIV感染的最先進技術,多類別合併藥物領域擁有最大的市場份額。這是由於在控制HIV和相關嚴重感染方面取得了更好的結果,並且易於管理和依從性,因此越來越多地使用該類藥物。

按地區,對北美,歐洲,亞太地區和LAMEA的市場進行了調查。由於愛滋病毒流行率的提高,艾滋病毒治療的進步以及政府對藥品生產研發的資助增加,北美地區在2015年的市場份額最大。此外,亞太地區還應歸功於主要公司對新興經濟體的興趣,主要是對接受各種疾病有效治療的人們的健康以及愛滋病毒傳播的增加。它具有最大的增長潛力。

本報告調查了全球HIV(人類免疫缺陷病毒)治療藥物市場,並按藥物類別/地區,市場趨勢,增長因素和限制因素分析了市場概況,市場規模趨勢和預測。它提供全面的信息,例如市場機會,競爭條件和主要公司的概況。

目錄

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
    • 2019年的關鍵成功策略
  • 主要公司的定位
    • 主要投資口袋
  • 波特的五力分析
  • 市場動態
    • 成長因素
      • 全世界越來越多的HIV感染患者
      • 各種政府機構採取的旨在提高對愛滋病毒/愛滋病診斷和管理意識的舉措
      • 介紹用於愛滋病治療的非專利藥
    • 抑制因素
      • 對HIV治療的批准和商業化的嚴格監管要求
    • 市場機會
      • 待售產品數量增加
    • 影響分析
  • COVID-19對HIV藥品市場的影響

第4章HIV治療市場:按藥物類別

  • 概述
    • 市場規模/預測
  • 多類複合藥物
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按地區
    • 市場分析:按國家
    • 多類複合藥物:按品牌
      • 市場規模/預測
      • Atripla、市場規模,預測
      • Complera、市場規模,預測
      • Prezcobix/prezista、市場規模,預測
      • Stribild、市場規模,預測
      • Genvoya、市場規模,預測
      • Odefsey、市場規模,預測
      • Symtuza、市場規模,預測
      • Trimeq、市場規模,預測
      • Descovy、市場規模,預測
      • 其他市場規模/預測
  • 核甘逆轉錄□抑制劑(NRTI)
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按地區
    • 市場分析:按國家
    • 核甘逆轉錄□抑制劑(NRTI):按品牌
      • 市場規模/預測
      • 恩曲他濱,市場規模/預測
      • Epiville,市場規模/預測
      • Epzicom,市場規模/預測
      • Tolbada,市場規模/預測
      • Biktavry,市場規模/預測
      • 其他市場規模/預測
  • 非核甘逆轉錄□抑制劑(NNRTI)
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按地區
    • 市場分析:按國家
    • 非核甘類逆轉錄□抑制劑(NNRTI):按品牌
      • 市場規模/預測
      • 教育者,市場規模/預測
      • 其他市場規模/預測
  • 祖細胞抑制劑(PI)
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按地區
    • 市場分析:按國家
    • 前驅抑制劑:按品牌
      • 市場規模/預測
      • Aptivus,市場規模/預測
      • Kaletra,市場規模/預測
      • Lexiva,市場規模/預測
      • Norvir,市場規模/預測
      • Villacept,市場規模/預測
      • 其他市場規模/預測
  • 侵襲抑制劑-CCR5共受體拮抗劑
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按地區
    • 市場分析:按國家
    • 入侵抑制劑-CCR5共受體拮抗劑:按品牌
      • Selzentry,市場規模/預測
  • HIV整合□鏈轉移抑製劑
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按地區
    • 市場分析:按國家
    • HIV整合□鏈轉移抑製劑:按品牌
      • 市場規模/預測
      • Isentress,市場規模/預測
      • Tivicay,市場規模/預測

第5章HIV治療市場:按地區

  • 概述
  • 北美
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按國家
      • 美國市場規模/預測:按藥品類別
      • 加拿大市場規模/預測:按藥品類別
      • 墨西哥市場規模/預測:按藥品類別
    • 北美,市場規模/預測:按藥品類別
  • 歐洲
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按國家
      • 德國市場規模/預測:按藥品類別
      • 法國市場規模/預測:按藥品類別
      • 英國市場規模/預測:按藥品類別
      • 意大利市場規模/預測:按藥品類別
      • 西班牙市場規模/預測:按毒品類別
      • 其他歐洲市場規模/預測:按藥品類別
    • 歐洲,市場規模/預測:按藥品類別
  • 亞太地區
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按國家
      • 日本市場規模/預測:按藥品類別
      • 中國市場規模/預測:按藥品類別
      • 印度市場規模/預測:按藥品類別
      • 澳大利亞市場規模/預測:按藥品類別
      • 其他亞太市場規模/預測:按藥品類別
    • 亞太地區,市場規模/預測:按藥品類別
  • 拉美
    • 主要市場趨勢,增長因素和機遇
    • 市場規模/預測:按國家
      • 巴西市場規模/預測:按藥品類別
      • 南非市場規模/預測:按藥品類別
      • 沙特阿拉伯市場規模/預測:按藥品類別
      • 其他LAMEA,市場規模/預測:按藥品類別
    • LAMEA,市場規模/預測:按藥品類別

第6章公司簡介

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GLAXOSMITHKLINE PLC. (ViiV Healthcare)
  • Johnson & Johnson
  • MERCK & CO., INC.
  • PFIZER INC.
  • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: A01537

Title:
Global HIV Drugs Market By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors): Opportunity Analysis and Industry Forecast, 2020-2027.

The global HIV drugs market was valued at $30,891.48 million in 2019, and is expected to reach $36,495.47 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.

Human immunodeficiency virus (HIV) attacks the body's immune system, leading to complete damage of the system and making the host system susceptible to infection. The virus attacks the CD4 cells, whose primary role is to help the immune system defend infections, thus destroying the first line of defense of the human body and exposing the person to various infections. HIV is one of the most alarming and widespread diseases globally. The major route of transmission of HIV infection is through unprotected sex, use of contaminated needles, breast milk of HIV-infected mother to child, and infected blood.

The global HIV drugs market is bifurcated into medication class and region. On the basis of medication class, the market is classified into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and HIV integrase strand transfer inhibitors. In the medication class, the multi-class combination drugs segment holds the largest market share as it involves the most advanced technique used for the treatment of HIV infection. Furthermore, this is attributed to the increase in adoption of drugs from this medication class, owing to their better results in the control of HIV & related co-infections and their ease in consumption & adherence.

Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in 2015, owing to increase in the number of HIV-infected individuals, advancement in HIV treatment, and rise in government funding for R&D for drug manufacturing. In addition, Asia-Pacific is expected to emerge with the maximum growth potential due to the focus of key players on emerging economies, mainly on the health of people with effective treatment for different diseases and rise in incidence of HIV infection.

The report provides a comprehensive analysis of key players that operate in the HIV drugs market such as Boehringer Ingelheim International GmbH, Merck & Co., Inc., Pfizer Inc., Gilead Sciences, Inc., GalaxoSmithKline plc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., AbbVie, and Cipla.

KEY BENEFITS FOR STAKEHOLDERS

The study provides in-depth analysis of the market along with the current trends and future estimations to explain the imminent investment pockets.

The report offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on the prevailing market opportunities.

The key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Medication Class

  • Multi-class Combination Drugs
  • Atripla
  • Complera
  • Prezcobix/Prezista
  • Stribild
  • Genvoya
  • Odefsey
  • Symtuza
  • Triumeq
  • Descovy
  • Others
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Emtriva
  • Epivir
  • Epzicom
  • Truvada
  • Biktarvy
  • Others
  • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Edurant
  • Others
  • Protease Inhibitors(PIs)
  • Aptivus
  • Kaletra
  • Lexiva
  • Norvir
  • Viracept
  • Others
  • Entry Inhibitors
  • Selzentry
  • HIV Integrase Strand Transfer Inhibitors
  • Isentress
  • Tivicay

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • List of key players profiled in the report
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • GalaxoSmithKline plc. (ViiV Healthcare)
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie
  • Cipla

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
    • 1.2.1.List of key players profiled in the report
  • 1.3.Research methodology
    • 1.3.1.Primary research
    • 1.3.2.Secondary research
    • 1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
    • 3.1.1.Top winning strategies, 2019
  • 3.2.Top player positioning
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Increase in number of HIV infected patients worldwide
      • 3.4.1.2.Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS
      • 3.4.1.3.Introduction of generic drugs of HIV drugs
    • 3.4.2.Restraint
      • 3.4.2.1.Stringent regulatory requirements for the approval and commercialization of HIV drugs
    • 3.4.3.Opportunity
      • 3.4.3.1.Increasing number of products in the pipeline
    • 3.4.4.Impact Analysis
  • 3.1.COVID-19 impact on the HIV Drugs market

CHAPTER 4:HIV DRUGS MARKET, BY MEDICATION CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.MULTICLASS COMBINATION DRUGS
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
    • 4.2.4.Multiclass combination drugs, By brand
      • 4.2.4.1.Market size and forecast
      • 4.2.4.2.Atripla, market size and forecast
      • 4.2.4.3.Complera, market size and forecast
      • 4.2.4.4.Prezcobix/prezista, market size and forecast
      • 4.2.4.5.Stribild, market size and forecast
      • 4.2.4.6.Genvoya, market size and forecast
      • 4.2.4.7.Odefsey, market size and forecast
      • 4.2.4.8.Symtuza, market size and forecast
      • 4.2.4.9.Trimeq, market size and forecast
      • 4.2.4.10.Descovy, market size and forecast
      • 4.2.4.11.Others, market size and forecast
  • 4.3.NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
    • 4.3.4.Nucleoside reverse transcriptase inhibitors (NRTIs), By brand
      • 4.3.4.1.Market size and forecast
      • 4.3.4.2.Emtriva, market size and forecast
      • 4.3.4.3.Epivir, market size and forecast
      • 4.3.4.4.Epzicom, market size and forecast
      • 4.3.4.5.Truvada, market size and forecast
      • 4.3.4.6.Biktavry, market size and forecast
      • 4.3.4.7.Others, market size and forecast
  • 4.4.NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
    • 4.4.4.Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), By brand
      • 4.4.4.1.Market size and forecast
      • 4.4.4.2.Edurant, market size and forecast
      • 4.4.4.3.Others, market size and forecast
  • 4.5.PROTEASE INHIBITORS (PIs)
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
    • 4.5.4.Protease Inhibitors, By brand
      • 4.5.4.1.Market size and forecast
      • 4.5.4.2.Aptivus, market size and forecast
      • 4.5.4.3.Kaletra, market size and forecast
      • 4.5.4.4.Lexiva, market size and forecast
      • 4.5.4.5.Norvir, market size and forecast
      • 4.5.4.6.Viracept, market size and forecast
      • 4.5.4.7.Others, market size and forecast
  • 4.6.ENTRY INHIBITORS - CCR5 co-receptor antagonist
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country
    • 4.6.4.Entry Inhibitors - CCR5 co-receptor antagonist, By brand
      • 4.6.4.1.Selzentry, market size and forecast
  • 4.7.HIV INTEGRASE STRAND TRANSFER INHIBITORS
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by region
    • 4.7.3.Market analysis, by country
    • 4.7.4.HIV integrase strand transfer inhibitors, By brand
      • 4.7.4.1.Market size and forecast
      • 4.7.4.2.Isentress, market size and forecast
      • 4.7.4.3.Tivicay, market size and forecast

CHAPTER 5:HIV DRUGS MARKET, BY REGION

  • 5.1.Overview

Market size and forecast

  • 5.2.North America
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by country
      • 5.2.2.1.U.S. market size and forecast, by medication class
      • 5.2.2.2.Canada market size and forecast, by medication class
      • 5.2.2.3.Mexico market size and forecast, by medication class
    • 5.2.3.North America, market size and forecast, by medication class
  • 5.3.Europe
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by country
      • 5.3.2.1.Germany market size and forecast, by medication class
      • 5.3.2.2.France market size and forecast, by medication class
      • 5.3.2.3.UK market size and forecast, by medication class
      • 5.3.2.4.Italy market size and forecast, by medication class
      • 5.3.2.5.Spain market size and forecast, by medication class
      • 5.3.2.6.Rest of Europe market size and forecast, by medication class
    • 5.3.3.Europe, market size and forecast, by medication class
  • 5.4.Asia-Pacific
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by country
      • 5.4.2.1.Japan market size and forecast, by medication
      • 5.4.2.2.China market size and forecast, by medication
      • 5.4.2.3.India market size and forecast, by medication
      • 5.4.2.4.Australia market size and forecast, by medication
      • 5.4.2.5.Rest of Asia-Pacific market size and forecast, by medication
    • 5.4.3.Asia-Pacific, market size and forecast, by medication class
  • 5.5.LAMEA
    • 5.5.1.Key market trends, growth factors, and opportunities
    • 5.5.2.Market size and forecast, by country
      • 5.5.2.1.Brazil market size and forecast, by medication class
      • 5.5.2.2.South Africa market size and forecast, by medication class
      • 5.5.2.3.Saudi Arabia market size and forecast, by medication class
      • 5.5.2.4.Rest of LAMEA, market size and forecast, by medication class
    • 5.5.3.LAMEA, market size and forecast, by medication class

CHAPTER 6:COMPANY PROFILES

  • 6.1.AbbVie Inc.
    • 6.1.1.Company overview
    • 6.1.2.Company snapshot
    • 6.1.3.Operating business segments
    • 6.1.4.Product portfolio
    • 6.1.5.Business performance
    • 6.1.6.Key strategic moves and developments
  • 6.2.Boehringer Ingelheim International GmbH
    • 6.2.1.Company overview
    • 6.2.2.Company snapshot
    • 6.2.3.Operating business segments
    • 6.2.4.Product portfolio
    • 6.2.5.Business performance
  • 6.3.Cipla Inc.
    • 6.3.1.Company overview
    • 6.3.2.Company snapshot
    • 6.3.3.Operating business segments
    • 6.3.4.Product portfolio
    • 6.3.5.Business performance
    • 6.3.6.Key strategic moves and developments
  • 6.4.F. Hoffmann-La Roche Ltd.
    • 6.4.1.Company overview
    • 6.4.2.Company snapshot
    • 6.4.3.Operating business segments
    • 6.4.4.Product portfolio
    • 6.4.5.Business performance.
  • 6.5.Gilead Sciences, Inc.
    • 6.5.1.Company overview
    • 6.5.2.Company snapshot
    • 6.5.3.Operating business segments
    • 6.5.4.Product portfolio
    • 6.5.5.Business performance
  • 6.6.GLAXOSMITHKLINE PLC. (ViiV Healthcare)
    • 6.6.1.Company overview
    • 6.6.2.Company snapshot
    • 6.6.3.Operating business segments
    • 6.6.4.Product portfolio
    • 6.6.5.Business performance
    • 6.6.6.Key strategic moves and developments
  • 6.7.Johnson & Johnson
    • 6.7.1.Company overview
    • 6.7.2.Company snapshot
    • 6.7.3.Operating business segments
    • 6.7.4.Product portfolio
    • 6.7.5.Business performance
  • 6.8.MERCK & CO., INC.
    • 6.8.1.Company overview
    • 6.8.2.Company snapshot
    • 6.8.3.Operating business segments
    • 6.8.4.Product portfolio
    • 6.8.5.Business performance
    • 6.8.6.Key strategic moves and developments
  • 6.9.PFIZER INC.
    • 6.9.1.Company snapshot
    • 6.9.2.Operating business segments
    • 6.9.3.Product portfolio
    • 6.9.4.Business performance
  • 6.10.Teva Pharmaceutical Industries Ltd.
    • 6.10.1.Company overview
    • 6.10.2.Company snapshot
    • 6.10.3.Operating business segments
    • 6.10.4.Product portfolio
    • 6.10.5.Business performance
    • 6.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 02.HIV DRUGS MARKET FOR MULTICLASS COMBINATION DRUG, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.MULTICALSS COMBINATION DRUGS MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 04.HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 06.HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 08.HIV DRUGS MARKET FOR PROTEASE INHIBITORS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.PROTEASE INHIBITORS MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 10.HIV DRUGS MARKET FOR ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 13.HIV DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.NORTH AMERICA HIV DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 15.U.S. HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 16.CANADA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 17.MEXICO HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 18.NORTH AMERICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 19.EUROPE HIV DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 20.GERMANY HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 21.FRANCE HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 22.UK HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 23.ITALY HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 24.SPAIN HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 25.REST OF EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 26.EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 27.ASIA-PACIFIC HIV DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 28.JAPAN HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 29.CHINA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 30.INDIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 31.AUSTRALIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 32.REST OF ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 33.ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 34.LAMEA HIV DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 35.BRAZIL HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 36.SOUTH AFRICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 37.SAUDI ARABIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 38.REST OF LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 39.LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 40.ABBVIE: COMPANY SNAPSHOT
  • TABLE 41.ABBVIE: OPERATING SEGMENTS
  • TABLE 42.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 43.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 44.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 45.GSK: OPERATING SEGMENTS
  • TABLE 46.GSK: PRODUCT PORTFOLIO
  • TABLE 47.CIPLA: COMPANY SNAPSHOT
  • TABLE 48.CIPLA: OPERATING SEGMENTS
  • TABLE 49.CIPLA: PRODUCT PORTFOLIO
  • TABLE 50.CIPLA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 51.ROCHE: COMPANY SNAPSHOT
  • TABLE 52.ROCHE: OPERATING SEGMENTS
  • TABLE 53.ROCHE: PRODUCT PORTFOLIO
  • TABLE 54.GILEAD: COMPANY SNAPSHOT
  • TABLE 55.GILEAD: OERATING SEGMENT
  • TABLE 56.GILEAD: PRODUCT PORTFOLIO
  • TABLE 57.GSK: COMPANY SNAPSHOT
  • TABLE 58.GSK: OPERATING SEGMENTS
  • TABLE 59.GSK: PRODUCT PORTFOLIO
  • TABLE 60.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 61.J&J: COMPANY SNAPSHOT
  • TABLE 62.J&J: OPERATING SEGMENTS
  • TABLE 63.J&J: PRODUCT PORTFOLIO
  • TABLE 64.MERCK : COMPANY SNAPSHOT
  • TABLE 65.MERCK : OPERATING SEGMENTS
  • TABLE 66.MERCK: PRODUCT PORTFOLIO
  • TABLE 67.MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 68.PFIZER: COMPANY SNAPSHOT
  • TABLE 69.PFIZER: OPERATING SEGMENTS
  • TABLE 70.PFIZER: PRODUCT PORTFOLIO
  • TABLE 71.TEVA: COMPANY SNAPSHOT
  • TABLE 72.TEVA: OPERATING SEGMENTS
  • TABLE 73.TEVA: PRODUCT PORTFOLIO
  • TABLE 74.TEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.GLOBAL HIV DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017-2020*
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2020*
  • FIGURE 04.TOP WINNING STRATEGIES: COMPANY , 2017-2020
  • FIGURE 05.TOP PLAYER POSITIONING, 2019
  • FIGURE 06.TOP INVESTMENT POCKETS
  • FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIER
  • FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.HIGH THREAT OF NEW ENTRANT
  • FIGURE 12.IMPACT ANALYSES, HIV DRUGS MARKET
  • FIGURE 13.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR MULTI CLASS COMBINATION DRUGS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 14.ATRIPLA MARKET, 2019-2027 ($MILLION)
  • FIGURE 15.COMPLERA MARKET, 2019-2027 ($MILLION)
  • FIGURE 16.PREZCOBIX/PREZISTA MARKET, 2019-2027 ($MILLION)
  • FIGURE 17.STRIBILD MARKET, 2019-2027 ($MILLION)
  • FIGURE 18.GENVOYA MARKET, 2019-2027 ($MILLION)
  • FIGURE 19.ODEFSEY MARKET, 2019-2027 ($MILLION)
  • FIGURE 20.SYMTUZA MARKET, 2019-2027 ($MILLION)
  • FIGURE 21.TRIMEQ MARKET, 2019-2027 ($MILLION)
  • FIGURE 22.DESCOVY MARKET, 2019-2027 ($MILLION)
  • FIGURE 23.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 24.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 25.EMTRIVA MARKET, 2019-2027 ($MILLION)
  • FIGURE 26.EPIVIR MARKET, 2019-2027 ($MILLION)
  • FIGURE 27.EPZICOM MARKET, 2019-2027 ($MILLION)
  • FIGURE 28.TRUVADA MARKET, 2019-2027 ($MILLION)
  • FIGURE 29.BIKTAVRY MARKET, 2019-2027 ($MILLION)
  • FIGURE 30.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 31.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 32.EDURANT MARKET, 2019-2027 ($MILLION)
  • FIGURE 33.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 34.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 35.APTIVUS MARKET, 2019-2027 ($MILLION)
  • FIGURE 36.KALETRA MARKET, 2019-2027 ($MILLION)
  • FIGURE 37.LEXIVA MARKET, 2019-2027 ($MILLION)
  • FIGURE 38.NORVIR MARKET, 2019-2027 ($MILLION)
  • FIGURE 39.VIRACEPT MARKET, 2019-2027 ($MILLION)
  • FIGURE 40.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 41.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR ENTRY INHIBITORS CCR5 CO RECEPTOR ANTAGONIST, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 42.SELZENTRY MARKET, 2019-2027 ($MILLION)
  • FIGURE 43.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 44.ISENTRESS MARKET, 2019-2027 ($MILLION)
  • FIGURE 45.TIVICAY MARKET, 2019-2027 ($MILLION)
  • FIGURE 46.ABBVIE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 47.ABBVIE: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 48.ABBVIE: REVENUE SHARE BY REGION, 2019(%)
  • FIGURE 49.BOEHRINGER INGELHEIM: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 50.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 51.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 52.CIPLA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 53.CIPLA: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 54.CIPLA: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 55.ROCHE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 56.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 57.ROCHE: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 58.GILEAD: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 59.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 60.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 61.GSK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 62.J&J: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 63.J&J: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 64.J&J: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 65.MERCK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 66.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 67.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 68.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 69.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 70.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 71.TEVA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 72.TEVA: REVENUE SHARE BY GEOGRAPHY, 2019 (%)